MPTP: A review of its mechanisms of neurotoxicity

Clinical Neuroscience Research

Volumn 1, Issue 6, 2001, Pages 407-418

  Przedborski, Serge ^a   Vila, Miquel ^a  

^a Howard Hughes Medical Institute   (United States)

Author keywords

Synuclein; 1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Apoptosis; Free radicals; Neurodegeneration; Nitric oxide; Parkinson's disease; Poly(ADP ribose) polymerase

Indexed keywords

EID: 0001485756     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1566-2772(01)00019-6     Document Type: Review

References (137)

1. Fahn S. Parkinsonism. In: Wyngaarden JB, Smith Jr LH, editors. Cecil's textbook of medicine, Philadelphia, PA: Saunders, 1988. pp. 2143-2147.
2. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991;41:202-205.
3. Beal MF. Experimental models of parkinson's disease. Nat Rev Neurosci 2001;2:325-334.
4. Przedborski S, et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 2001;76:1265-1274.
5. Langsten JW, Ballard P, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
6. Langston JW, Irwin I. MPTP: current concepts and controversies. Clin Neuropharmacol 1986;9:485-507.
7. Heikkila RE, Sieber BA, Manzino L, Sonsalla PK. Some features of the nigrostriatal dopaminergic neurotoxin 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Mol Chemic Neuropathol 1989;10:171-183.
8. Kopin IJ, Markey SP. MPTP toxicity: implication for research in Parkinson's disease. Annu Rev Neurosci 1988;11:81-96.
9. Langston JW. MPTP: the promise of a new neurotoxin. In: Marsden CD, Fahn S, editors. Movement disorders 2, London: Butterworths, 1987. pp. 73-90.
10. Vingerhoets FJ, et al. Positron emission tomographic evidence for progression of human MPTP- induced dopaminergic lesions. Ann Neurol 1994;36:765-770.
11. Langston JW, et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999;46:598-605.
12. Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. In: Marsden CD, Fahn S, editors. Movement disorders 2, London: Butterworths, 1987. pp. 166-230.
13. Seniuk NA, Tatton WG, Greenwood CE. Dose-dependent destruction of the coeruleus-cortical and nigral- striatal projections by MPTP. Brain Res 1990;527:7-20.
14. Muthane U, et al. Differences in nigral neuron number and sensitivity to 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine in C57/b1 and CD-1mice. Exp Neurol 1994;126:195-204.
15. Moratalla R, et al. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1992;89:3859-3863.
16. Snow BJ, et al. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J Neurol Neurosurg Psychiatry 2000;68:313-316.
17. Forno LS, DeLanney LE, Irwin I, Langston JW. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease: neuropathologic considerations. Adv Neurol 1993;60:600-608.
18. Betarbet R, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-1306.
19. DiMauro S. Mitochondrial involvement in Parkinson's disease: The controversy continues. Neurology 1993;43:2170-2172.
20. Nicklas WJ, Yougster SK, Kindt MV, Heikkila RE. MPTP, MPP + and mitochondrial function. Life Sci 1987;40:721-729.
21. Gluck MR, Youngster SK, Ramsay RR, Singer TP, Nicklas WJ. Studies on the characterization of the inhibitory mechanism of 4′-alkylated 1-methyl-4-phenylpyridinium and phenylpyridine analogues in mitochondria and electron transport particles. J Neurochem 1994;63:655-661.
22. Przedborski S, Jackson-Lewis V. Experimental developments in movement disorders: update on proposed free radical mechanisms. Curr Opin Neurol 1998;11:335-339.
23. Przedborski S, et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity. J Neurosci 1992;12: 1658-1667.
24. Schulz JB, Matthews RT, Muqit MMK, Browne SE, Beal MF. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 1995;64:936-939.
25. Hantraye P, et al. Inhibition of neuronal nitric oxide synthase prevents MPTP- induced parkinsonism in baboons. Nature Med 1996;2:1017-1021.
26. Przedborski S, Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov Disord 1998;13(Suppl 1):35-38.
27. Mayer RA, Kindt MV, Heikkila RE. Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4- dihydroxyphenylethylamine transport. J Neurochem 1986;47:1073-1079.
28. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridinium by dopamine neurons explain selective toxicity. Proc Natl Acad Sci USA 1985;82:2173-2177.
29. Bezard E, et al. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol 1999;155:268-273.
30. Donovan DM, et al. Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. Dev Brain Res 1999;73:37-49.
31. Liu Y, Roghani A, Edwards RH. Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium. Proc Natl Acad Sci USA 1992;89:9074-9078.
32. Ramsay RR, Singer TP. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine, by mitochondria. J Biol Chem 1986;261:7585-7587.
33. +: evidence for a new mechanism involving hydride transfer with xanthine oxidase, aldehyde dehydrogenase, and lipoamide dehydrogenase. Free Radic Biol Med 1993;15:169-179.
34. Takahashi N, et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 1997;94:9938-9943.
35. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by MPP + , a metabolite of the neurotoxin MPTP. Life Sci 1985;36:2503-2508.
36. Mizuno Y, Sone N, Saitoh T. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J Neurochem 1987;48:1787-1793.
37. Ramsay RR, et al. Interaction of 1-methyl-4-phenylpyridinium ion (MPP +) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase. J Neurochem 1991;56:1184-1190.
38. 3H]dihydrorotenone binding to NADH: Ubiquinone reductase (Complex I) of the electron transport chain: an autoradiographic study. J Neurosci 1996;16:3807-3816.
39. Davey GP, Clark JB. Threshold effects and control of oxidative phosphorylation in nonsynaptic rat brain mitochondria. J Neurochem 1996;66:1617-1624.
40. Chan P, DeLanney LE, Irwin I, Langston JW, Di Monte D. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in mouse brain. J Neurochem 1991;57:348-351.
41. Rossetti ZL, Sotgiu A, Sharp DE, Hadjiconstantinou M, Neff M. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro. Biochem Pharmacol 1988;37:4573-4574.
42. Hasegawa E, Takeshige K, Oishi T, Murai Y, Minakami S. 1-Mehtyl-4-phenylpyridinium(MPP +) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem Biophys Res Commun 1990;170:1049-1055.
43. Cleeter MW, Cooper JM, Schapira AH. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 1992;58:786-789.
44. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995;4:257-269.
45. Tatton NA, Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997;77:1037-1048.
46. Vila M, et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2001;98:2837-2842.
47. Burke RE, Kholodilov NG. Programmed cell death: does it play a role in Parkinson's disease? Ann Neurol 1998;44:S126-S133.
48. Halliwell B, Gutteridge JM. Free radicals in biology and medicine. Oxford: Clarendon Press, 1991.
49. 2 in the production of HO-: in vitro and in vivo. Free Radic Biol Med 1994;16:29-33.
50. Teismann P, Schwaninger M, Weih F, Ferger B. Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease. NeuroReport 2001;12:1049-1053.
51. Pennathur S, Jackson-Lewis V, Przedborski S, Heinecke JW. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and 0,0'-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6- tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J Biol Chem 1999;274:34621-34628.
52. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-1624.
53. Huie RE, Padmaja S. The reaction of NO with superoxide. Free Radie Res Commun 1993;18:195-199.
54. Wink DA, Matthews RT, Grisham MB, Mitchell JB, Ford PC. Direct and indirect effects of nitric oxide in chemical reactions relevant to biology. In: Packer L, editor. Nitric oxide. Part A. Source and detection of NO; NO synthase, New York: Academic Press, 1996. pp. 12-31.
55. Beckman JS, Chen J, Crow JP, Ye YZ. Reactions of nitric oxide, superoxide and peroxynitrite with superoxide dismutase in neurodegeneration. Prog Brain Res 1994;103:371-380.
56. Przedborski S, et al. Role of neuronal nitric oxide in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 1996;93:4565-4571.
57. Moore PK, Wallace P, Gaffen Z, Hart SL, Babbedge RC. Characterization of the novel nitric oxide synthase inhibitor 7-nitro indazole and related indazoles: antinociceptive and cardiovascular effects. Br J Pharmacol 1993;110:219-224.
58. Castagnoli K, Palmer S, Anderson A, Bueters T, Castagnoli Jr. N. The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem Res Toxicol 1997;10:364-368.
59. Di Monte D, et al. Inhibition of monoamine oxidase contributes to the protective effect of 7-nitroindazole against MPTP neurotoxicity. J Neurochem 1997;69:1771-1773.
60. Matthews RT, Yang LC, Beal MF. S-methylthiocitrulline, a neuronal nitric oxide synthase inhibitor, protects against malonate and MPTP neurotoxicity. Exp Neurol 1997;143:282-286.
61. Bredt DS, et al. Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron 1991;7:615-624.
62. Leonard CS, Kerman I, Blaha G, Taveras E, Taylor B. Interdigitation of nitric oxide synthase-, tyrosine hydroxylase-, and serotonin-containing neurons in and around the laterodorsal and pedunculopontine tegmental nuclei of the guinea pig. J Comp Neurol 1995;362:411-432.
63. Lancaster Jr JR. Diffusion of free nitric oxide. In: Packer L, editor. Nitric oxide. Source and detection of NO; NO synthase, New York: Academic Press, 1996. pp. 31-50.
64. Huang PL, Dawson TM, Bredt DS, Snyder SH, Fishman MC. Targeted disruption of the neuronal nitric oxide synthase gene. Cell 1993;75:1273-1285.
65. Dawson TM, Dawson VL. Generation of isoform-specific antibodies to nitric oxide synthases. In: Packer L, editor. Nitric oxide. Sources and detection of NO; NO synthase, New York: Academic Press, 1996. pp. 349-358.
66. Lowenstein CJ, Glatt CS, Bredt DS, Snyder SH. Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. Proc Natl Acad Sci USA 1992;89:6711-6715.
67. Keilhoff G, et al. Patterns of nitric oxide synthase at the messenger RNA and protein levels during early rat brain development. Neuroscience 1996;75:1193-1201.
68. Simmons ML, Murphy S. Induction of nitric oxide synthase in glial cells. J Neurochem 1992;59:897-905.
69. Liberatore GT, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999;5:1403-1409.
70. Beckman JS. Peroxynitrite versus hydroxyl radical: the role of nitric oxide in superoxide-dependent cerebral injury. Ann NY Acad Sci 1994;738:69-75.
71. Uppu RM, Squadrito GL, Cueto R, Pryor WA. Selecting the most appropriate synthesis of peroxynitrite. In: Packer L, editor. Nitric oxide. Physiological and pathological processes, New York: Academic Press, 1996. pp. 285-295.
72. Ohshima H, Friesen M, Brouet I, Bartsch H. Nitrotyrosine as a new marker for endogenous nitrosation and nitration of proteins. Fd Chem Toxic 1990;28:647-652.
73. Van der Vliet HJ, Eiserich JP, Kaur H, Cross CE, Halliwell B. Nitrotyrosine as biomarker for reactive nitrogen species. Methods Enzymol 1996;269:175-184.
74. Mihm MJ, et al. Free 3-nitrotyrosine causes striatal neurodegeneration in vivo. J Neurosci 2001;21:RC149.
75. Ischiropoulos H, et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 1992;298:431-437.
76. Trotti D, et al. Peroxynitrite inhibits glutamate transporter subtypes. J Biol Chem 1996;271:5976-5979.
77. Kong C-K, Yim MB, Stadtman ER, Chock PB. Peroxynitrite disables the tyrosine phosphorylation regulatory mechanism: Lymphocyte-specific tyrosine kinase fails to phosphorylate nitrated cdc2(6-20)NH2 peptide. Proc Natl Acad Sci USA 1996;93:3377-3382.
78. Martin BL, Wu D, Jakes S, Graves DJ. Chemical influences on the specificity of tyrosine phosphorylation. J Biol Chem 1990;265:7108-7111.
79. Ara J, et al. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc Natl Acad Sci USA 1998;95:7659-7663.
80. Sanchez-Ramos JR, Övervik E, Ames BN. A marker of oxyradical-mediated DNA damage (8-Hydroxy-2′deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 1994;3:197-204.
81. Alam ZI, et al. Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997;69:1196-1203.
82. Byun J, Henderson JP, Mueller DM, Heinecke JW. 8-Nitro-2′-deoxyguanosine, a specific marker of oxidation by reactive nitrogen species, is generated by the myeloperoxidase-hydrogen peroxide-nitrite system of activated human phagocytes. Biochemistry 1999;38:2590-2600.
83. Szabo C, Zingarelli B, O'Connor M, Salzman AL. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci USA 1996;93:1753-1758.
84. Szabo C. DNA strand breakage and activation of poly-ADP ribosyl-transferase: a cytotoxic pathway triggered by peroxynitrite. Free Radic Biol Med 1996;21:855-869.
85. Lindahl T, Satoh MS, Poirier GG, Klungland A. Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem Sci 1995;20:405-411.
86. Zhang J, Pieper A, Snyder SH. Poly(ADP-ribose) synthetase activation: an early indicator of neurotoxic DNA damage. J Neurochem 1995;65:1411-1414.
87. Cosi C, Marien M. Decreases in mouse brain NAD + and ATP induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide. Brain Res 1998;809:58-67.
88. Mandir AS, et al. Poly (ADP-ribose) polymerase activation mediates MPTP-induced parkinsonism. Proc Natl Acad Sci USA 1999;96:5774-5779.
89. Vila M, Jackson-Lewis V, Guégan C, et al. The role of glial cells in Parkinson's disease. Curr Opin Neurol 2001 In press.
90. Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I, Czlonkowski A. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 1996;5:137-143.
91. Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I, Czlonkowski A, Czlonkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 1998;39:167-180.
92. Przedborski S, Jackson-Lewis V, Djaldetti R, et al. The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 2000;16:135-142.
93. O'Callaghan JP, Miller DB, Reinhard JF. Characterization of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-l,2,3,6- tetrahydropyridine. Brain Res 1990;521:73-80.
94. Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 2000;74:2213-2216.
95. Seibert K, Masferrer J, Zhang Y, et al. Mediation of inflammation by cyclooxygenase-2. Agents Actions Suppl 1995;46(41-50):41-50.
96. anion O'B, Cyclooxygenase-2: MK. molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 1999;13:45-82.
97. Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 1996;93:2317-2321.
98. Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem 1994;269:13725-13728.
99. Knott C, Stern G, Wilkin GP. Inflammatory regulators in Parkinson's Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2. Mol Cell Neurosci 2000;16:724-739.
100. Mattammal MB, Strong R, Lakshmi VM, Chung HD, Stephenson AH. Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease. J Neurochem 1995;64:1645-1654.
101. Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001;39:167-174.
102. Fornstedt B. Role of catechol autooxidation in the degeneration of dopamine neurons. Acta Neurol Scand Suppl 1990;129:12-14.
103. Markstein R, Lahaye D. Neurochemical investigations in vitro with 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine (MPTP) in preparations of rat brain. Eur J Pharmacol 1984;106:301-311.
104. Pileblad E, Nissbrandt H, Carlsson A. Biochemical and functional evidence for a marked dopamine releasing action of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (NMPTP) in mouse brain. J Neural Transm 1984;60:199-203.
105. Schmidt CJ, Matsuda LA, Gibb JW. In vitro release of tritiated monoamines from rat CNS tissue by the neurotoxic compound 1-methyl-phenyl-tetrahydropyridine. Eur J Pharmacol 1984;103:255-260.
106. Chang GD, Ramirez VD. The mechanism of action of MPTP and MPP + on endogenous dopamine release from the rat corpus striaturn superfused in vitro. Brain Res 1986;368:134-140.
107. Rollema H, Damsma G, Horn AS, De Vries JB, Westerink BH. Brain dialysis in conscious rats reveals an instantaneous massive release of striatal dopamine in response to MPP +. Eur J Pharmacol 1986;126:345-346.
108. Obata T, Chiueh CC. In vivo trapping of hydroxyl free radicals in the striatum utilizing intracranial microdialysis perfusion of salicylate: effects of MPTP, MPDP + , and MPP + . J Neural Transm Gen Sect 1992;89:139-145.
109. Lotharius J, O'Malley KL. Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity. Ann Neurol 2001;49:79-89.
110. Polymeropoulos MH, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
111. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mla30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 1998;18:107-108.
112. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998;95:6469-6473.
113. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat Med 1998;4:1318-1320.
114. El-Agnaf OM, Jakes R, Curran MD, et al. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett 1998;440:71-75.
115. El-Agnaf OM, Jakes R, Curran MD, Wallace A. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Lett 1998;440:67-70.
116. Engelender S, Kaminsky Z, Guo X, et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet 1999;22:110-114.
117. Giasson BI, Uryu K, Trojanowski JQ, Lee VM. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 1999;274:7619-7622.
118. Narhi L, et al. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 1999;274:9843-9846.
119. Przedborski S, Chen Q, Vila M, et al. Oxidative post-translational modifications of alpha-synuclein in the 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Neurochem 2001;76:637-640.
120. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha- synuclein nitration in synucleinopathy lesions. Science 2000;290:985-989.
121. Vila M, Vukosavic S, Jackson-Lewis V, et al. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 2000;74:721-729.
122. Hashimoto M, Hsu LJ, Xia Y, et al. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha- synuclein in vitro. NeuroReport 1999;10:717-721.
123. Kakimura J, Kitamura Y, Takata K, et al. Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur J Pharmacol 2001;417:59-67.
124. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000;287:1265-1269.
125. van der Putten H, Wiederhold KH, Probst A, et al. Neuropathology in mice expressing human alpha-synuclein. J Neurosci 2000;20: 6021-6029.
126. Matsuoka Y, Vila M, Lincoln S, et al. Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis 2001 in press.
127. Rathke-Hartlieb S, Kahle PJ, Neumann M, et al. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. J Neurochem 2001;77:1181-1184.
128. Hassouna I, Wickert H, Zimmermann M, Gillardon F. Increase in bax expression in substantia nigra following 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment of mice. Neurosci Lett 1996;204:85-88.
129. Hartmann A, Hunot S, Michel PP, et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 2000;97:2875-2880.
130. Yang L, Mattews RT, Schulz JB, et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci 1998;18:8145-8152.
131. Offen D, Beart PM, Cheung NS, et al. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Proc Natl Acad Sci USA 1998;95:5789-5794.
132. Xu D, Bureau Y, McIntyre DC, et al. Attenuation of ischemia-induced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus. J Neurosci 1999;19:5026-5033.
133. Eberhardt O, Coelln RV, Kugler S, et al. Protection by synergistic effects of adenovirus-mediated X-chromosome- linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine model of Parkinson's disease. J Neurosci 2000;20:9126-9134.
134. Hartmann A, Troadec JD, Hunot S, et al. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci 2001;21:2247-2255.
135. Trimmer PA, Smith TS, Jung AB, Bennett Jr. JP. Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity. Neurodegeneration 1996;5:233-239.
136. Saporito MS, Thomas BA, Scott RW. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J Neurochem 2000;75:1200-1208.
137. Saporito MS, Brown EM, Miller MS, Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J Pharmacol Exp Ther 1999;288:421-427.